CHANNEL THERAPEUTICS CORP (CHRO)
US1711261057 - Common Stock
CHANNEL THERAPEUTICS CORP
NYSEARCA:CHRO (12/18/2024, 8:10:53 PM)
After market: 0.6199 +0.03 (+5.07%)0.59
-0.03 (-4.76%)
Company Profile
Chromocell Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. The company is headquartered in North Brunswick, New Jersey and currently employs 4 full-time employees. The firm's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.
Company Info
CHANNEL THERAPEUTICS CORP
685 US Highway One
North Brunswick NEW JERSEY
P: 19176446313
Employees: 4
Website: https://chromocell.com/
CHRO News
14 hours ago - Channel Therapeutics CorporationChannel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block ModelFREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the...
12 days ago - ChartmillFriday's after hours session: top gainers and losersAfter hours stock analysis on 2024-12-06: top gainers and losers in today's session.
a month ago - Channel Therapeutics CorporationChromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates“Channel Therapeutics” reflects the Company’s focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulationNew name is in...
2 months ago - Chromocell Therapeutics CorporationChromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical PainFREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer...
2 months ago - Chromocell Therapeutics CorporationChromocell to Present at Upcoming Fall Investor ConferencesFREEHOLD, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer...
2 months ago - Chromocell Therapeutics CorporationChromocell Announces Amendment to Stock Repurchase PlanFREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer...
CHRO Twits
Here you can normally see the latest stock twits on CHRO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
